{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:32:23Z","timestamp":1763141543536},"reference-count":55,"publisher":"Georg Thieme Verlag KG","issue":"04\/05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Reprod Med"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The global incidence of breast cancer is increasing, as is the efficacy of treatments. Consequently, increasing survival rates reinforce the importance of survivorship issues, including posttreatment menopausal symptoms, sexual function, and mental health and well-being. Breast cancer patients can experience a range of menopausal symptoms associated with their treatment. Most commonly women may experience vasomotor symptoms, including hot flushes and night sweats. Particularly for women on maintenance tamoxifen therapy, up to 80% will experience hot flushes, with almost one-third of these women reporting severe symptoms. Breast cancer patients may also experience genitourinary symptoms of menopause, which may include vaginal dryness and irritation, dyspareunia, and dysuria. Hormonal therapy has long been established as the most effective treatment for vasomotor symptoms. However, the hormonal nature of breast malignancies renders systemic hormone therapies unsuitable for these patients, posing a unique treatment challenge, which may result in clinicians not feeling confident to manage them. Consequently, this review outlines pharmacological and nonpharmacological options for women with bothersome menopausal symptoms after breast cancer treatment and provides practical, evidence-based guidance for clinicians.<\/jats:p>","DOI":"10.1055\/s-0041-1726467","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T07:25:32Z","timestamp":1617261932000},"page":"309-314","source":"Crossref","is-referenced-by-count":2,"title":["Management of Early Menopause\/Premature Ovarian Insufficiency in Women with or at High Risk of Breast Cancer"],"prefix":"10.1055","volume":"38","author":[{"given":"Annabelle","family":"Brennan","sequence":"additional","affiliation":[{"name":"Royal Women's Hospital, Parkville, Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Hickey","sequence":"additional","affiliation":[{"name":"Royal Women's Hospital, Parkville, Victoria Australia"},{"name":"Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1016\/S2214-109X(20)30215-1","article-title":"Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study","volume":"8","author":"E Heer","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"S S Faubion","year":"2015","journal-title":"Climacteric"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of the North American Menopause Society","volume":"24","author":"The NAMS 2017 Hormone Therapy Position Statement Advisory Panel","year":"2017","journal-title":"Menopause"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/GME.0b013e3182976f46","article-title":"Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history","volume":"21","author":"J L Marino","year":"2014","journal-title":"Menopause"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/13697137.2019.1646718","article-title":"Managing menopausal symptoms after cancer","volume":"22","author":"R A Szabo","year":"2019","journal-title":"Climacteric"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1758834016687260","article-title":"A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy","volume":"9","author":"M S Sousa","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1111\/jsm.12684","article-title":"Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors","volume":"11","author":"L R Schover","year":"2014","journal-title":"J Sex Med"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jnci\/djr541","article-title":"Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review","volume":"104","author":"J Howard-Anderson","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"07","key":"ref9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/gme.0b013e318204af9d","article-title":"Potential adverse impact of ovariectomy on physical and psychological function of younger women with breast cancer","volume":"18","author":"P Sayakhot","year":"2011","journal-title":"Menopause"},{"issue":"36","key":"ref10","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1200\/JCO.2008.16.8377","article-title":"Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy","volume":"26","author":"Y Jin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"30","key":"ref11","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1200\/JCO.2007.10.8274","article-title":"Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy","volume":"25","author":"S E Jones","year":"2007","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"S Wills","year":"2012","journal-title":"J Oncol Pract"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/01.AOG.0000241091.86268.6e","article-title":"Breast cancer risk in postmenopausal women using estrogen-only therapy","volume":"108","author":"H Lyytinen","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study","volume":"25","author":"C J Crandall","year":"2018","journal-title":"Menopause"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study","volume":"135","author":"I Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1097\/AOG.0000000000001351","article-title":"ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer","volume":"127","author":"ACOG","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/GME.0000000000001121","article-title":"Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health","volume":"25","author":"S S Faubion","year":"2018","journal-title":"Menopause"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1210\/jc.2019-01603","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"104","author":"S R Davis","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.maturitas.2011.09.003","article-title":"Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial","volume":"70","author":"P Sismondi","year":"2011","journal-title":"Maturitas"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2018-01345","article-title":"Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors","volume":"103","author":"S R Davis","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"M E Melisko","year":"2017","journal-title":"JAMA Oncol"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11606-013-2535-9","article-title":"SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials","volume":"29","author":"T Shams","year":"2014","journal-title":"J Gen Intern Med"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000297371.89129.b3","article-title":"Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial","volume":"111","author":"L Speroff","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/gme.0b013e31818c91ca","article-title":"Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis","volume":"16","author":"A Bardia","year":"2009","journal-title":"Menopause"},{"issue":"17","key":"ref26","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1001\/jama.295.17.2057","article-title":"Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis","volume":"295","author":"H D Nelson","year":"2006","journal-title":"JAMA"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000348564","article-title":"Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials","volume":"75","author":"Z Sun","year":"2013","journal-title":"Gynecol Obstet Invest"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.2010.2016","article-title":"Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial","volume":"305","author":"E W Freeman","year":"2011","journal-title":"JAMA"},{"issue":"09","key":"ref29","first-page":"CD004923","article-title":"Non-hormonal interventions for hot flushes in women with a history of breast cancer","author":"G Rada","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3322\/caac.21171","article-title":"Risk factors, pathophysiology, and treatment of hot flashes in cancer","volume":"63","author":"W I Fisher","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"ref31","first-page":"1","article-title":"Position statement: non-hormonal management of menopause-associated vasomotor symptoms: 2015 position statement of the North American Menopause Society","volume":"22","year":"2015","journal-title":"Menopause"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/B:BREA.0000010676.54597.22","article-title":"Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer","volume":"83","author":"K J Pandya","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","article-title":"Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial","volume":"366","author":"K J Pandya","year":"2005","journal-title":"Lancet"},{"issue":"02","key":"ref34","first-page":"50","article-title":"Managing the menopause without hormones","volume":"21","author":"A Brennan","year":"2020","journal-title":"Med Today"},{"issue":"29","key":"ref35","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1200\/JCO.2010.33.1298","article-title":"Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"A H Boekhout","year":"2011","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdl478","article-title":"Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study","volume":"18","author":"S Loibl","year":"2007","journal-title":"Ann Oncol"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-008-0138-7","article-title":"Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study","volume":"115","author":"C Buijs","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/13697137.2020.1789093","article-title":"Managing vasomotor symptoms effectively without hormones","volume":"23","author":"C A McCormick","year":"2020","journal-title":"Climacteric"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamainternmed.2018.0116","article-title":"Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial","volume":"178","author":"C M Mitchell","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"30","key":"ref41","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","article-title":"A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial","volume":"33","author":"M F Goetsch","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref42","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/GME.0000000000000546","article-title":"Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society","volume":"22","author":"North American Menopause Society","year":"2015","journal-title":"Menopause"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(11)70364-3","article-title":"Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial","volume":"13","author":"E Mann","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1200\/JCO.18.00655","article-title":"Efficacy of internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a randomized controlled trial","volume":"37","author":"V Atema","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref45","first-page":"CD001395","article-title":"Phytoestrogens for menopausal vasomotor symptoms","author":"A Lethaby","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11764-016-0585-9","article-title":"Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors","volume":"11","author":"J Carter","year":"2017","journal-title":"J Cancer Surviv"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/GME.0000000000000672","article-title":"Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and\/or hormonal therapy for breast cancer: a retrospective study","volume":"23","author":"T Pagano","year":"2016","journal-title":"Menopause"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/GME.0000000000000761","article-title":"Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors","volume":"24","author":"M Gambacciani","year":"2017","journal-title":"Menopause"},{"issue":"03","key":"ref49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13697130701361657","article-title":"IMS updated recommendations on postmenopausal hormone therapy","volume":"10","author":"A Pines","year":"2007","journal-title":"Climacteric"},{"issue":"03","key":"ref50","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/cen.13735","article-title":"Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia","volume":"89","author":"M Grossmann","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"T J Powles","year":"1996","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"L Vehmanen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"22","key":"ref53","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2007.12.3430","article-title":"Bone density in breast cancer: when to intervene?","volume":"25","author":"J R Gralow","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref54","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data","volume":"4","author":"D Zhu","year":"2019","journal-title":"Lancet Public Health"},{"issue":"07","key":"ref55","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1210\/js.2019-00096","article-title":"Cardiometabolic effects of endocrine treatment of estrogen receptor-positive early breast cancer","volume":"3","author":"Y M Cheung","year":"2019","journal-title":"J Endocr Soc"},{"issue":"05","key":"ref56","doi-asserted-by":"crossref","first-page":"e182140","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome sequencing-based screening for BRCA1\/2 expected pathogenic variants among adult Biobank participants","volume":"1","author":"K Manickam","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"08","key":"ref58","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"J Kotsopoulos","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Seminars in Reproductive Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1726467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T22:38:59Z","timestamp":1619563139000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1726467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":55,"journal-issue":{"issue":"04\/05","published-online":{"date-parts":[[2021,4,27]]},"published-print":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1726467","relation":{},"ISSN":["1526-8004","1526-4564"],"issn-type":[{"value":"1526-8004","type":"print"},{"value":"1526-4564","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}